Aptagel Plasmonic Fiber Optic Biosensor for In Vivo Continuous Drug Monitoring.
Satapathy P., Park S., Pal A., Santa C., Koros E., Schweimer J., Hasler R., Dostalek J., Clark H., Arban R., Hengerer B., Sergelen K.
Continuous monitoring of drug dynamics directly in living tissue remains a major challenge, notably in the brain, where the blood-brain barrier creates distinct microenvironments. Here, we report an implantable fiber optic surface plasmon resonance (FO-SPR) biosensor coated with aptagel, a split-aptamer-crosslinked hydrogel, for continuous monitoring of a small-molecule drug, vancomycin. The aptagel undergoes analyte-induced volumetric and refractive index changes, providing a self-contained means for reversible, label-free optical detection via shifts in the SPR wavelength (λSPR) while ensuring sensor stability in complex physiological matrices. The sensing area was miniaturized to 3 mm2 (3 mm length, 300 μm diameter) for cortical implantation while maintaining sensitivity of >2000 nm/RIU. The sensor performed consistently in vitro across diverse biological media, including blood serum, with detection limits of 1.7-2.5 μM. Upon implantation into the rat cortex, time-resolved λSPR signals were recorded over several hours after intravenous vancomycin administration, representing to our knowledge the first demonstration of plasmonic fiber-based monitoring of a small-molecule drug directly in brain tissue. Baseline-corrected shifts (ΔλSPR) captured in vivo drug dynamics, with a consistent absorption phase but with inter-animal variability in peak amplitude and clearance kinetics. This work establishes a proof-of-concept platform for continuous optical monitoring in deep tissue and highlights the potential of FO-SPR sensing for in vivo pharmacokinetic applications.
